RxDoctor Payments Data

Leila Neshatian, MD

Gastroenterology · Stanford, CANPI 1710275722

Payments from drug & device makers

$29,472in general payments, 2019–2025

Across 29 payments — averaging $1016.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironwood Pharmaceuticals, Inc$19K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$7K
  • Ardelyx, Inc.$2K
  • GI Supply, Inc.$1K
  • Medtronic$186
  • Vibrant Gastro, Inc.$142
  • plus $377 from 5 others

What the payments were for

  • Consulting fees$8,10027%
  • Speaking & faculty fees$1,1254%
  • Grants$18,55063%
  • Food & beverage$1,6976%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,472 in reported general payments places this provider in the 80th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$88,265
Medicare patients
442
Services billed
1,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide54$57,875
IbsrelaTenapanor Hcl17$35,078
MotegrityPrucalopride Succinate36$26,134
TrulancePlecanatide19$11,528
Colesevelam Hcl13$977
Omeprazole21$532
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg15$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$72$57,87554 claims
Ardelyx, Inc.Ibsrela$1,855$35,07817 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$7,237$11,52819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →